Survivors living with advanced cancer after durable response to immune therapy
Official title: A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
Funded at Roswell Park Cancer Institute Corp · NIH-11401364 · Data updated 2026-11-12
This grant follows people who had advanced cancer and responded well to immune checkpoint inhibitors to understand what helps them stay well and how their symptoms change over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $755,795 |
| NIH project number | 5R01CA281862-04 |
| Project ID | NIH-11401364 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with advanced cancer who have achieved a durable response to immune checkpoint inhibitors, including lung, kidney, and melanoma cancer types.
✕Less likely to help
Patients who did not achieve a durable response or who are not treated with ICIs may not benefit from this study.
What this research studies
The study combines a large look back at medical records from patients who received immune checkpoint inhibitors and a forward-looking group of about 1,200 patients with durable responses. Researchers will collect clinical data and patient-reported outcomes every six months to map long-term survival, physical health, and psychosocial well-being. The aim is to identify factors associated with lasting benefit and to describe the survivorship needs of these patients in real-world settings. By comparing different cancer types and treatments, the project seeks to inform better follow-up care and support for people living with advanced cancer after a strong response to ICIs.
Why it matters
Potential benefit: If successful, patients could receive more personalized follow-up care and resources to manage long-term effects and improve quality of life.
How similar studies have gone: Previous work has shown clear benefits of long-term follow-up in cancer survivorship, but this project adds detailed, multi-institution data and patient-reported outcomes for ICI responders.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Yao, Song — Roswell Park Cancer Institute Corp
- Study coordinator: Yao, Song
Related research
Other NIH-funded projects on the same topics.
-
Survivorship after lasting benefit from immunotherapy for advanced cancer
This project follows people with advanced cancers who have had long-lasting benefit from immunotherapy to track their health, symptoms, and care needs over time.
-
Understanding how some advanced cancer patients benefit long-term from immune therapies
This study is looking at patients with advanced cancer who have had lasting positive results from certain immune treatments, to learn more about what helps them live longer and how to support their needs better.
-
Understanding how survivorship care plans affect health outcomes for cancer survivors
A study will look at whether survivorship care plans help reduce deaths and improve health for adults who have survived cancer.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.